美国慢性乙型肝炎的晚期诊断:2007至2021年基于人群的回顾性队列研究
结果显示76.6%为晚期诊断,其中44.5%在索引并发症时或6个月内确诊,75.5%无就诊记录;晚期诊断率2009年73.8%与2017年74.2%保持稳定(p-trend=0.937)。
要点
- 约四分之三(76.6%)的CHB患者为晚期诊断,其中44.5%在并发症时或6个月内确诊。
- 晚期诊断率2009年73.8%与2017年74.2%保持稳定(p-trend=0.937)。
- 晚期诊断组并发症包括肝硬化91.0%、失代偿期肝硬化81.5%、肝细胞癌30.8%、肝移植14.4%。
核心结论
- 在美国,约四分之三确诊的CHB患者为晚期诊断,需加强筛查以预防不良临床结局。
主要发现
- 2608例患者平均年龄54.8岁,70.3%为男性。
- 1999例(76.6%)为晚期诊断,其中889例(44.5%)在索引并发症时或6个月内确诊,1510例(75.5%)至索引日期无就诊记录。
- 晚期诊断率2009年73.8%与2017年74.2%保持稳定(p-trend=0.937)。
- 晚期诊断组并发症包括肝硬化(n=1820,91.0%)、失代偿期肝硬化(n=1630,81.5%)、肝细胞癌(n=615,30.8%)和肝移植(n=288,14.4%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Underdiagnosis of chronic hepatitis B (CHB) remains a major problem in the United States (USA), with > 80% of CHB patients remaining undiagnosed. AIMS: To determine the prevalence of late diagnosis of CHB and resultant liver complications. METHODS: This retrospective analysis of the Truven MarketScan database (1/2007-12/2021) included more than 250 million privately insured persons. The index date was the date of the first liver complication (cirrhosis, hepatocellular carcinoma [HCC], or liver transplant). Late diagnosis was defined as the diagnosis of CHB 2 years prior to or after the index date. Adults aged ≥ 18 years with a diagnosis of CHB and ≥ 12 months of insurance coverage prior to the index date were included. Exclusion criteria included > 90 days break of insurance coverage within 12 months before the index date and receipt of nonliver transplant within 5 years of the index date. RESULTS: 2608 persons met inclusion criteria with a mean age of 54.8 years and 70.3% were male. 1999 (76.6%) had a late diagnosis of CHB, of whom 889 (44.5%) were diagnosed at or within 6 months of the index complication, and 1510 (75.5%) did not have a documented visit with a provider to the index date. Late diagnosis rate remained stable between 2009 (73.8%) and 2017 (74.2%, p-trend = 0.937). In the late diagnosis group, complications included cirrhosis (n = 1820, 91.0%), decompensated cirrhosis (n = 1630, 81.5%), HCC (n = 615, 30.8%) and liver transplant (n = 288, 14.4%). CONCLUSION: Approximately three-fourths of patients diagnosed with CHB in the USA had a late diagnosis. Increased screening efforts must be made to prevent poor clinical outcomes.
引用
- Le MH, Liu JK, Lee K, et al. Late Diagnosis of Chronic Hepatitis B in the United States: A Population-Based, Retrospective Cohort Study From 2007 to 2021. Aliment Pharmacol Ther. 2025. PMID: 40418666. doi:10.1111/apt.70193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。